Drugs in MeSH Category Dopamine Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	DIHYDROERGOTAMINE MESYLATE	dihydroergotamine mesylate	SPRAY, METERED;NASAL	212907-001	May 20, 2020	AB	RX	No	No
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	9,044,475		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	8,846,074		Y
Trupharma	APOMORPHINE HYDROCHLORIDE	apomorphine hydrochloride	INJECTABLE;SUBCUTANEOUS	212025-001	Feb 23, 2022	AP	RX	No	No

Dopamine Agonists Market Analysis and Financial Projection

The global dopamine agonist market is experiencing steady growth driven by increasing demand for neurological treatments, with significant innovations in drug development and formulation. The patent landscape reflects ongoing research to enhance therapeutic efficacy and address limitations of existing therapies. Below is a detailed analysis of market dynamics and patent trends:

---

Market Dynamics

Current Valuation and Growth Projections

• The market was valued at $1.31 billion in 2024 and is projected to reach $1.83 billion by 2030, growing at a 5.70% CAGR [1][4][11]. Conflicting estimates suggest a higher 2022 valuation of $4.5 billion (growing to $6.9 billion by 2027 at an 8.5% CAGR), likely due to differing regional or methodological scopes [7].

Key Growth Drivers

1. Rising Neurological Disorder Prevalence: Parkinson’s disease (PD), restless legs syndrome (RLS), and hyperprolactinemia are primary drivers. PD alone accounts for a $4.5 billion drug market [2][11].

2. Formulation Advancements:

   • Oral agonists (e.g., ropinirole, pramipexole) dominate chronic disease management due to convenience [1][4].
   • Injectable formulations (e.g., apomorphine) address acute PD symptoms and advanced-stage cases [11].
   • Non-ergot agonists (e.g., pramipexole, rotigotine) are preferred over ergot-derived drugs (e.g., bromocriptine) for improved safety [1][11].

3. Regional Insights:

   • North America leads due to high R&D investments, FDA approvals (e.g., Mirapex, Requip), and strong biopharmaceutical infrastructure [11].
   • Europe and Asia-Pacific are growing with government-backed biotech initiatives and expanding clinical trials [11][15].
   • China and Brazil show rapid growth driven by local manufacturing and rising healthcare expenditures [11][15].

Competitive Landscape

• Major players include GlaxoSmithKline, Teva, and Novartis, with dominance in FDA-approved drugs like carbidopa/levodopa and ropinirole [15].
• Pipeline Innovations:
  • Tavapadon (D1/D5 selective agonist) and IRL1117 (D1/D2 agonist) aim to reduce dyskinesia and impulse control issues [11].
  • Extended-release and transdermal formulations improve patient adherence [11].

---

Patent Landscape

Key Innovations and Strategic Developments	Patent Focus	Examples & Applications	Significance	Source
Selective D-2 Agonists	PPHT (2-(N-phenylethyl-N-propylamino)-5-hydroxytetralin)	Targets D-2 receptors for reduced side effects	[8]
Drug Repositioning	Amantadine (extended-release for PD/RLS)	Patent-protected formulations for new indications	[5]
Bivalent Agonists	D-679 (dual D2/D3 agonist with neuroprotective properties)	Inhibits alpha-synuclein aggregation in PD	[9]
Non-Catechol Agonists	Compound 1 (D1R-selective with minimal β-arrestin recruitment)	Reduces desensitization and tachyphylaxis	[10]
Therapeutic Biomarkers	Plasma/urine analysis for dopamine metabolite ratios	Identifies optimal candidates for agonist therapy	[13]

Emerging Trends

• AI and Automation: Accelerate drug discovery and optimize clinical trials [7].
• Multifunctional Agonists: Compounds like D-634 combine dopaminergic activity with neuroprotection [9].
• Pain Management: Morpholine-based agonists (e.g., Pfizer’s patent) target chronic nociceptive pain [14].

---

Challenges and Opportunities

• Generic Competition: Mainstay drugs like levodopa and carbidopa are off-patent, driving demand for novel therapies [2].
• Safety Concerns: Ergot-derived agonists face declining use due to fibrosis risks, favoring non-ergot alternatives [1][11].
• Precision Medicine: Biomarker-driven approaches (e.g., metabolic profiling) could personalize treatment [13].

---

Future Outlook
The dopamine agonist market will expand further through receptor-specific drugs, advanced delivery systems, and AI-driven R&D. Innovations addressing side effects and improving bioavailability (e.g., non-catechol agonists) are poised to redefine therapeutic standards.

References

1. https://www.researchandmarkets.com/reports/6056059/dopamine-agonist-market-size-share-and-trends
2. https://www.maxval.com/blog/pharma-patent-landscape-parkinsons-disease-uncovered/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9368481/
4. https://www.grandviewresearch.com/press-release/global-dopamine-agonist-market
5. https://www.openaccessjournals.com/articles/Amantadine-and-Phenytoin-Patent-Protected-Cases-of-Drug-Repositioning.pdf
6. https://pubs.acs.org/doi/10.1021/acsomega.8b00884
7. https://sites.google.com/view/real-timebusinessresearchinsig/reports/dopamine-agonist-market
8. https://patents.justia.com/patent/4465692
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC9898996/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8175458/
11. https://www.grandviewresearch.com/industry-analysis/dopamine-agonist-market-report
12. https://meshb.nlm.nih.gov/record/ui?ui=D018492
13. https://pubchem.ncbi.nlm.nih.gov/patent/US8137992
14. https://www.patentsencyclopedia.com/app/20090318451
15. https://www.databridgemarketresearch.com/reports/global-dopamine-agonist-drug-market